MK-677 on TikTok: separating real GH data from bro-science

What did @davidj.rau actually say?

In a million-view TikTok, @davidj.rau ran through MK-677 (ibutamoren) basics with a few confident claims and one notable sales pitch at the end. He called it a growth hormone secretagogue, listed expected benefits including "increased fat-free muscle mass," "increased REM sleep," and a "huge spike in appetite," and flagged insulin sensitivity as the main downside. He also said it "doesn't snag your nadicard" - presumably meaning it does not suppress natural testosterone production the way anabolic steroids or actual SARMs do. The video closes with a direct referral to his Instagram link tree to purchase what he calls a "research can."

That last part is worth flagging upfront: MK-677 is not approved by the FDA for human use. It is sold as a "research chemical," a label that creates legal cover but does not make it safe or standardized for personal use. The sales referral in the video does not mention this context at all.

Does the science back this up?

Partially. The core pharmacology is accurate: MK-677 does stimulate GH secretion by mimicking ghrelin and acting on pituitary receptors. The appetite claim is also well-supported. But the muscle mass and endurance claims are significantly overstated relative to what the clinical evidence actually shows.

On the GH and IGF-1 side, the science is solid. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) confirmed that MK-677 sustained elevated GH and IGF-1 levels over two years in older adults. Thorner et al. (1997, Journal of Clinical Endocrinology and Metabolism) showed similar acute GH pulse amplification. The REM sleep improvement has some support too: Copinschi et al. (1997, Sleep) found increased REM sleep duration in young adults taking MK-677. So the mechanism and a few specific effects check out.

Where it gets shakier is "increased fat-free muscle mass." The Nass 2008 trial did show lean mass gains, but also significant increases in fat mass and, critically, worsening insulin resistance. The endurance claim has essentially no robust clinical backing in the current literature.

What did they get wrong (or right)?

Right: MK-677 is not a SARM. This is a common and genuinely harmful misconception, and giving it a clear correction is useful. MK-677 works on ghrelin receptors, not androgen receptors, so it does not carry the same androgenic side effect profile. The "doesn't snag your nadicard" comment, however garbled, is pointing at a real distinction: MK-677 does not appear to suppress endogenous testosterone or require post-cycle therapy the way androgenic compounds do. That part is mostly accurate.

Wrong: The appetite mechanism is described backwards. He said MK-677 "antagonizes ghrelin," but that is incorrect. MK-677 is a ghrelin receptor agonist, meaning it mimics ghrelin, not blocks it. This is not a minor semantic error. Antagonizing ghrelin would suppress appetite. Agonizing it is why you feel like you can eat through a wall. The effect he described is real; the explanation he gave is the opposite of the mechanism producing it.

Also wrong by omission: he mentions "control that" regarding insulin sensitivity, as if it is a manageable footnote. The Nass 2008 data showed meaningful increases in fasting glucose and insulin resistance over two years. For anyone with prediabetes or metabolic risk factors, that is not a side note.

What should you actually know?

MK-677 is not approved for human use. It is an investigational compound that has been studied in clinical trials, but those trials were conducted under controlled medical supervision with monitored dosing and regular bloodwork. Buying it from a social media link tree and self-administering without baseline labs is a materially different situation than what the research describes.

The side effect profile deserves more than a one-liner. Documented concerns include increased appetite leading to fat gain, water retention, elevated fasting glucose, and in long-term studies, potential increases in cortisol. There are also open questions about cancer risk in susceptible populations, since IGF-1 elevation is associated with cell proliferation pathways. None of this means MK-677 is uniquely dangerous compared to other compounds in this space, but it does mean the risk calculus requires more than a TikTok video to assess responsibly.

If you are curious about growth hormone secretagogues as part of a clinical protocol, that conversation belongs with a licensed clinician who can order baseline IGF-1, fasting glucose, and HbA1c before anything else. The "do your own research" sign-off followed immediately by a purchase link is not a substitute for that.